DexCom, Inc. reported second-quarter 2025 adjusted earnings per share of 48 cents, surpassing projections by 6.7%. This figure was an increase from the previous year’s EPS of 43 cents.

Revenues rose 15.2% to $1.16 billion, exceeding expectations by 3.1%. Growth was driven by strong demand, particular success in type 2 diabetes sectors, and recent access wins.

Despite these results, DXCM shares fell by 5.5% post-trading on 30 July, although they have risen 9.9% this year. This is against the backdrop of a 7.3% decline in the industry.

The sensor and other revenues, forming 97% of total revenues, grew by 18% to $1.12 billion. In contrast, hardware revenues decreased by 31% to $39.3 million.

U.S. revenues increased 15% to $841 million, while international revenues grew 16% to $316.1 million. However, the adjusted gross margin fell to 60.1%, down by 340 basis points year over year.

DexCom reported a 9% rise in research and development expenses to $148.2 million. Adjusted operating income increased by 13.5% to $221.8 million, with margins slightly down.

The company anticipates 2025 revenues of $4.6-$4.625 billion, reflecting a 14-15% growth. The gross margin is expected to reach approximately 62%.

Product innovation includes the upcoming 15-day G7 sensor, and over 400,000 downloads of the new Stelo biosensor app. Moreover, they are launching an AI-powered Smart Food Logging feature for enhanced diabetes management.

Despite near-term margin pressures, the company remains optimistic about gross margin guidance. Kevin Sayer will step down as CEO in early 2026, with Jake Leach set to succeed him.

The proposed competitive bidding program for Medicare CGM could pose challenges, but DexCom remains confident with its strong market position. The company is expanding with access to approximately 6 million new lives, aiming for 25 million. With significant cash reserves and a growing customer base, DexCom is well-positioned in the CGM market.

We are observing a classic “sell the news” scenario with DexCom following its July 30th earnings report. Despite beating revenue and earnings estimates, the stock’s 5.5% drop signals that the market is focused on shrinking gross margins. This pressure on profitability is the key takeaway for us, outweighing the strong top-line growth for now.

From a derivatives standpoint, this event has significantly altered the options landscape. Implied volatility for DXCM, which we saw spike to over 60% before the announcement, has already started to contract sharply toward the 45% level. This post-earnings volatility crush means selling options premium is becoming more attractive than buying it.

The market’s concern over margins is amplified by external factors. Reports from mid-July 2025 confirmed that key competitor Abbott received an accelerated FDA review for its next-generation Libre 4 sensor, fueling worries about a price war. We believe this backdrop makes it unlikely that DXCM shares will break out to new highs in the immediate term.

Looking back at the stock’s history, we saw similar post-earnings dips in both late 2023 and mid-2024. In those instances, strong user growth was also overshadowed by concerns about future profitability, leading to short-term weakness. This historical pattern suggests the current pullback is a recurring theme rather than a new crisis.

Given the strong underlying growth drivers like the new Stelo biosensor and expanding market access, a complete collapse in the stock price seems unlikely. The sell-off may present an opportunity for strategies that bet on a price floor, such as selling out-of-the-money put spreads. This allows us to collect premium while defining our risk, should the margin concerns cause further temporary dips.

For the coming weeks, we anticipate the stock will likely enter a consolidation phase as traders weigh the positive sales growth against the negative margin pressure. The upcoming CEO transition in 2026 adds another layer of long-term uncertainty but should have minimal impact on short-term trading. Therefore, we are considering strategies that profit from the stock trading within a defined range.